SCHEMBL27292

SCHEMBL27292

OCCCc1ccccc1CO

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.49
CYP4A11 Q02928 2/20 0.49
APOBEC3G Q9HC16 1/20 0.44
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.41
MPO P05164 2/20 0.39
SLC6A4 P31645 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
LTA4H P09960 1/20 0.37
EPHX2 P34913 1/20 0.37
LIPG Q9Y5X9 1/20 0.36
MGLL Q99685 1/20 0.36
TSHR P16473 1/20 0.36
CYP2A6 P11509 1/20 0.35
GLS O94925 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1607140 0.92 TDP1 (0.43) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
SCHEMBL29681348 0.92 TDP1 (0.43) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
SCHEMBL29681353 0.92 TDP1 (0.43) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
1,6-Hexanediol SCHEMBL28386159 0.84 APOBEC3G (0.48) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
SCHEMBL9672220 0.84 LIPG (0.43) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
SCHEMBL30563551 0.84 APOBEC3G (0.48) CYP4F2CYP4A11APOBEC3GMPOTDP1
SCHEMBL30750761 0.84 LIPG (0.43) CYP4F2CYP4A11APOBEC3GPOLBKDM4E
SCHEMBL27891 0.84 APOBEC3G (0.48) CYP4F2CYP4A11APOBEC3GMPOTDP1
SCHEMBL169275 0.83 TAAR1 (0.58) KDM4EMPOSLC6A4TAAR1MGLL
SCHEMBL2178352 0.82 LIPG (0.47) CYP4F2CYP4A11APOBEC3GPOLBMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
US-10336717-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, LLC (US) 2019-07-02 US disclosed
EP-2754638-B1 FILM-FORMING MATERIAL, GROUP IV METAL OXIDE FILM AND VINYLENE DIAMIDE COMPLEX TOSOH CORP (JP) 2018-11-07 EP disclosed
CN-105001254-B The manufacturing method of film material, IV family metal oxide films 东曹株式会社 2018-09-11 CN disclosed
US-20180110824-A1 Macrocyclic Modulators of the Ghrelin Receptor OCERA THERAPEUTICS, INC. 2018-04-26 US disclosed
US-20180110824-A1 Macrocyclic Modulators of the Ghrelin Receptor OCERA THERAPEUTICS, INC. 2018-04-26 US disclosed
EP-2939996-B1 GROUP 5 METAL OXO-ALKOXO COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR MANUFACTURING GROUP 5 METAL OXIDE FILM TOSOH CORP (JP) 2018-03-21 EP disclosed
EP-2339594-B1 COMPOSITION FOR PRODUCING METAL FILM, METHOD FOR PRODUCING METAL FILM, AND METHOD FOR PRODUCING METAL POWDER TOSOH CORP (JP) 2018-01-03 EP disclosed
EP-2457893-B1 Intermediates for macrocyclic modulators of the ghrelin receptor OCERA THERAPEUTICS INC (US) 2017-08-16 EP disclosed
US-9663541-B2 Group 5 metal oxo-alkoxo complex, method for producing same, and method for manufacturing group 5 metal oxide film TOSOH CORPORATION (JP) 2017-05-30 US disclosed
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor TRANZYME PHARMA INC. 2007-01-25 US disclosed
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor TRANZYME PHARMA INC. 2007-01-25 US disclosed
EP-1689712-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS Novartis AG (CH) 2006-08-16 EP disclosed
CN-1748012-A Adhesive tape for sticking wafer FURUKAWA ELECTRIC CO LTD (JP) 2006-03-15 CN disclosed
WO-2006009645-A1 METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR TRANZYME PHARMA, INC. (US) 2006-01-26 WO disclosed
CN-1661790-A Particle removing member of substrate processing equipment NITTO DENKO CORP (JP) 2005-08-31 CN disclosed
WO-2005051911-A1 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS NOVARTIS AG (CH) 2005-06-09 WO disclosed
US-4517327-A AMINO RESIN, STYRENE-(METH)ALLYL ALCOHOL COMPOLYER, ACRYLIC OR POLYESTER RESIN MONSANTO COMPANY (US) 1985-05-14 US disclosed
US-4031290-A ALPHA-BETA MONOMERS, CATALYSIS PPG INDUSTRIES, INC. (US) 1977-06-21 US disclosed
US-4016332-A OF ETHYLENICALLY UNSATURATED MONOMERS PPG INDUSTRIES, INC. (US) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180110824-A1 Macrocyclic Modulators of the Ghrelin Receptor GHSR, GIPR, GHRHR CYP4F2 3092/4885CYP4A11 877/4885APOBEC3G 4872/4885
US-10336717-B2 Inhibitors of beta-secretase BACE1, BACE2, PSEN1 CYP4F2 3082/4885CYP4A11 1014/4885APOBEC3G 2971/4885
US-20070021331-A1 Methods of using macrocyclic modulators of the ghrelin receptor GHSR, GHRHR, GIPR CYP4F2 2948/4885CYP4A11 896/4885APOBEC3G 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.